Duality Advisers’s TG Therapeutics TGTX Stock Holding History

Duality Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-104,487	Closed	-$994K	–	854
2022 Q1	$994K	Buy	+104,487	New	+$1.21M	0.11%	319

Other funds holding TGTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Duality Advisers's TGTX Position: Q2 2022 in Review

Duality Advisers sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 104,487 shares — an estimated $994K sold.

Duality Advisers first reported a position in TGTX in Q1 2022 and held it in 1 quarter. The position peaked at $994K in Q1 2022. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

Duality Advisers reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
Duality Advisers sold 104,487 TG Therapeutics shares in Q2 2022, an estimated $994K.
Duality Advisers first reported a position in TG Therapeutics in Q1 2022 and held it in 1 quarter.
Duality Advisers's TG Therapeutics position peaked at $994K in Q1 2022.
174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.